Molecular Partners Ag Stock Net Income
| MLLCF Stock | USD 2.25 0.10 4.26% |
As of the 29th of January, Molecular Partners secures the Standard Deviation of 4.84, mean deviation of 1.58, and Risk Adjusted Performance of (0.07). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Molecular Partners, as well as the relationship between them. Please verify Molecular Partners variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if Molecular Partners AG is priced some-what accurately, providing market reflects its recent price of 2.25 per share. Please also check out Molecular Partners jensen alpha, which is currently at (0.48) to check the company can sustain itself at a future point.
Molecular Partners' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Molecular Partners' valuation are provided below:Molecular Partners AG does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Molecular |
Molecular Partners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Partners' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Partners.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Molecular Partners on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Partners AG or generate 0.0% return on investment in Molecular Partners over 90 days. Molecular Partners is related to or competes with Innate Pharma, NDT Pharmaceuticals, Brii Biosciences, Scancell Holdings, JW Therapeutics, NervGen Pharma, and Ascend Wellness. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and... More
Molecular Partners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Partners' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Partners AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 48.13 | |||
| Value At Risk | (3.61) |
Molecular Partners Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Partners' standard deviation. In reality, there are many statistical measures that can use Molecular Partners historical prices to predict the future Molecular Partners' volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | 0.6309 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Molecular Partners' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Molecular Partners January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 0.6409 | |||
| Mean Deviation | 1.58 | |||
| Coefficient Of Variation | (913.87) | |||
| Standard Deviation | 4.84 | |||
| Variance | 23.38 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | 0.6309 | |||
| Maximum Drawdown | 48.13 | |||
| Value At Risk | (3.61) | |||
| Skewness | (4.50) | |||
| Kurtosis | 33.4 |
Molecular Partners Backtested Returns
Molecular Partners has Sharpe Ratio of -0.12, which conveys that the firm had a -0.12 % return per unit of risk over the last 3 months. Molecular Partners exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Molecular Partners' Risk Adjusted Performance of (0.07), standard deviation of 4.84, and Mean Deviation of 1.58 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.85, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Molecular Partners are expected to decrease slowly. On the other hand, during market turmoil, Molecular Partners is expected to outperform it slightly. At this point, Molecular Partners has a negative expected return of -0.63%. Please make sure to verify Molecular Partners' kurtosis, and the relationship between the total risk alpha and day typical price , to decide if Molecular Partners performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.71 |
Almost perfect reverse predictability
Molecular Partners AG has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Molecular Partners time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Partners price movement. The serial correlation of -0.71 indicates that around 71.0% of current Molecular Partners price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.71 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.18 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Molecular Partners AG reported net income of (63.78 Million). This is 118.69% lower than that of the Healthcare sector and 191.06% lower than that of the Biotechnology industry. The net income for all United States stocks is 111.17% higher than that of the company.
Molecular Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Partners' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics of similar companies.Molecular Partners is currently under evaluation in net income category among its peers.
Molecular Fundamentals
| Return On Equity | 0.62 | |||
| Return On Asset | 0.32 | |||
| Profit Margin | 0.62 % | |||
| Operating Margin | 0.61 % | |||
| Current Valuation | (41.92 M) | |||
| Shares Outstanding | 36.04 M | |||
| Shares Owned By Insiders | 14.13 % | |||
| Shares Owned By Institutions | 45.00 % | |||
| Price To Earning | 1.74 X | |||
| Price To Book | 0.91 X | |||
| Price To Sales | 1.19 X | |||
| Revenue | 9.33 M | |||
| Gross Profit | (45.96 M) | |||
| EBITDA | (60.67 M) | |||
| Net Income | (63.78 M) | |||
| Cash And Equivalents | 267.13 M | |||
| Cash Per Share | 8.22 X | |||
| Total Debt | 5.15 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 14.37 X | |||
| Book Value Per Share | 7.73 X | |||
| Cash Flow From Operations | (90.95 M) | |||
| Earnings Per Share | 3.82 X | |||
| Number Of Employees | 163 | |||
| Beta | 0.62 | |||
| Market Capitalization | 237.9 M | |||
| Total Asset | 172.67 M | |||
| Z Score | 27.6 | |||
| Net Asset | 172.67 M |
About Molecular Partners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Partners AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Partners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Partners AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Molecular Pink Sheet
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.